Drug addiction is marked by continued drug-seeking behavior despite deleterious consequences and a heightened propensity to relapse not withstanding long, drug-free periods. The enduring nature of addiction has been hypothesized to arise from perturbations in intracellular signaling, gene expression, and brain circuitry induced by substance abuse. Ameliorating some of these aberrations should abate behavioral and neurochemical markers associated with an 'addiction phenotype'. This review summarizes data showing that protein expression and signaling through the nonreceptor activator of G-protein signaling 3 (AGS3) are altered by commonly abused substances in rat and in in-vitro addiction models. AGS3 structure and function are unrelated to the more broadly studied regulator of G-protein signaling family. Thus, the unique role of AGS3 is the focus of this review. Intriguingly, AGS3 protein changes persist into drug abstinence. Accordingly, studies probing the role of AGS3 in the neurochemistry of drug-seeking behavior and relapse are studied in detail. To illuminate this study, AGS3 structure, cellular localization, and function are covered so that an idealized AGS3-targeted pharmacotherapy can be proposed.
Introduction
Addiction is becoming increasingly understood as a neuropathological disorder comprising chronic and compulsive drug relapse episodes during which the drive to seek and use drugs often cannot be controlled (O'Brien, 1996; Heyman, 2009 ). The enduring nature of addiction and a high-relapse liability even after extended abstinence has led to the hypothesis that drugs of abuse displace normal molecular machinery of reward-related associative learning (Koob et al., 1998; Hyman and Malenka, 2001; Jones and Bonci, 2005; Hyman et al., 2006; Kalivas and O'Brien, 2008) . Intriguingly, the mechanisms underlying relapse can be dissociated from those involved in drug reinforcement and dependence (Shaham et al., 1996; Cornish and Kalivas, 2000; Grimm and See, 2000) . Thus, pharmacotherapeutics that promote abstinence without interference with nondrug-derived reinforcement may arise from a thorough understanding of drug-mediated perturbations in second messenger systems.
Modeling drug relapse
Much work examining the behavioral and molecular responses to commonly abused substances has been accomplished in protocols where drugs are administered to laboratory subjects by the researcher. Two of these paradigms, behavioral sensitization and conditioned place preference, have contributed much to our knowledge (Le et al., 2001; Robinson and Berridge, 2008; Vezina and Leyton, 2009 ). Nonetheless, a growing literature has highlighted significantly different outcomes following researcher-administered or subject-administered, operant self-administration paradigms (Dworkin et al., 1995; Hemby et al., 1997 Hemby et al., , 2005 Markou et al., 1999; Jacobs et al., 2002 Jacobs et al., , 2003 Jacobs et al., , 2004 Jacobs et al., , 2005 Chen et al., 2008) and it is postulated that the molecular mechanisms of drug relapse can be probed with various manipulations of operant drug selfadministration paradigms (Davis and Smith, 1976; De Wit and Stewart, 1981; Le and Shaham, 2002; Shaham et al., 2003; Epstein et al., 2006) . In operant self-administration addiction models, the subject manipulates some operandum, such as a lever or nosepoke, resulting in responsecontingent drug delivery. Operant paradigms have been developed for nearly all substances abused by humans and these models can be used to quantify the motivation to seek drugs (Richardson and Roberts, 1996; Salamone et al., 2009) and to examine the choice structure of drug pursuit (Whitelaw et al., 1996; Ping and Kruzich, 2008) .
Addiction and the mesocorticolimbic system: general concepts
All drugs of abuse, albeit through different mechanisms, increase extracellular levels of the neuromodulator dopamine (Nestler, 2005) . Once released and before being sequestered into the presynaptic terminal, dopamine can activate both presynaptic and postsynaptic heterotrimeric G-protein-coupled dopamine receptors. Increased signaling through dopamine receptors has been shown to facilitate learning and/or incentive salience (Berridge and Robinson, 1998; Berke and Hyman, 2000; Jay, 2003) and can also change the gene expression and function (Berke and Hyman, 2000; Canales, 2005; Nestler, 2005) of circuitry that normally processes motivationally relevant environmental stimuli and adaptive goal-directed responding (Koob et al., 1998; Kelley, 2004) . The intricate modulation of motivated behavior and learning by mesocorticolimbic dopamine receptors has been reviewed earlier (Berke and Hyman, 2000; Nicola et al., 2000; El-Ghundi et al., 2007; Dalley and Everitt, 2009) as has the role of other heterotrimeric Gprotein-coupled receptors in the enduring nature of drug and alcohol-induced plasticity (Hack and Christie, 2003; Waldhoer et al., 2004; Gravanis and Margioris, 2005; Ong and Kerr, 2005; Cowen and Lawrence, 2006; Ferre et al., 2008; Abbracchio et al., 2009; Dalley and Everitt, 2009; Olive, 2009 ). Thus dopamine action within the mesocorticolimbic system or 'motive circuit' (Fig. 1) (Mogenson, 1993) has been an active area of investigation. Within the mesocorticolimbic system, the addiction literature has primarily focused on the ventral tegmental area and substantia nigra, dorsal and ventral striatum, amygdala, and frontal cortical regions that are referred to as the rat prefrontal cortex (PFC) or human anterior cingulate cortex (Ongur and Price, 2000; Goldstein and Volkow, 2002) . Important reviews have covered the complex circuitry recruited during the different behavioral phases of and situations leading to drug relapse (Leshner and Koob, 1999; See et al., 2003; Kalivas and Volkow, 2005; Rebec and Sun, 2005; Kalivas et al., 2006) . Included among these is the glutamatergic projection from the PFC into the nucleus accumbens core (NAcore) that seems essential for cue or drug-prime to precipitate relapse into cocaine-seeking or heroin-seeking behavior (Park et al., 2002; McFarland et al., 2003; McFarland et al., 2004; LaLumiere and Kalivas, 2008) and, as will be discussed below, may be under the control of the intracellular nonreceptor Activator of G-protein Signaling 3 (AGS3) and some members of the Regulators of Gprotein Signaling (RGS) family. As the role of the RGS family in addiction has been reviewed earlier (Neubig, 2002; Burchett, 2005; Ron and Jurd, 2005; Traynor and Neubig, 2005; Garzon et al., 2008; Hooks et al., 2008; Lomazzi et al., 2008; Traynor, 2010) , the focus here is on reviewing data implicating the apparent role of AGS3 in the medial ventral striatum (NAcore) and the PFC in shaping addiction-associated and alcoholism-associated aberrant signaling through G-protein-coupled receptors, neurochemistry, and behavior.
G-protein-coupled receptors
Appreciation of the intracellular signaling cascades that mediate biological effects of receptor activation largely began with description of the heterotrimeric guanine nucleotide-binding proteins (G-proteins) as a necessary interface between metabotropic cell surface receptors, such as dopamine, and enzymes, such as adenylyl cyclase (AC), that generate intracellular signaling molecules (Gilman, 1987; Ross, 1989) . Thus, heterotrimeric G-proteins are now known to transmit and amplify signal while serving as a primary level of integration and signal sorting (Gilman, 1987; Bourne and Nicoll, 1993; Neer, 1995) . Figure 2a illustrates canonical G-protein signal transduction across the cell membrane. However, the precise molecular events of the G-protein cycle are not fully elucidated (Oesterhelt and Stoeckenius, 1971; Stickle and Barber, 1993; Tian and Deth, 1993; Bourne, 1997; Hamm, 2001) . For example, intrinsic guanosine triphosphate (GTP) hydrolytic rate constants (Breitwieser and Szabo, 1988 ) of reconstituted Ga are slower than that of crude membrane preparations Ross, 1985, 1986; Sato et al., 1995) . This discrepancy in rate constants is only partially explained should diffusion kinetics alter subcellular compartmentalization (Lamb and Pugh, 1992) . Thus, the search for G-protein accessory proteins, such as AGS3 and the RGS family, began.
G-protein relevance to addiction
Disruptions in G-protein kinetics or subcellular stoichiometry have been described in several disease states (Manji, 1992; Ostrom et al., 2000) , including alcohol (Waltman et al., 1993; Pattiselanno et al., 1994; Ferguson and Goldberg, 1997; Nestby et al., 1999) , opiate (Griffin et al., 1985; De Vries et al., 1991; Suzuki et al., 1991; Terwilliger et al., 1991; Van Vliet et al., 1991 , 1993 Guitart Fig. 1 Mesocortical Mesolimbic NAcore PFC VTA NAshell Some 'motive' circuit nuclei. The mesocorticolimbic circuit parses reward valence and motivational drives to execute both novel as well as habitual responding (Mogenson et al., 1993) . Two of these regions are the focus of this review; the nucleus accumbens core (NAcore) and the prefrontal cortex (PFC). Both the NAcore and PFC receive dopaminergic afferents from the ventral tegmental area (VTA). Importantly, glutamatergic projections from the PFC into the NAcore (open arrow) are necessary for the reinstatement of seeking behavior in several models of drug relapse (Park et al., 2002; McFarland et al., 2003 McFarland et al., , 2004 LaLumiere and Kalivas, 2008) . NAshell, nucleus accumbens shell.
AGS3 structure, expression, and function Bowers 501 et al., 1993; Ronken et al., 1994; Self et al., 1994; Schoffelmeer et al., 1995 Schoffelmeer et al., , 1997 Nestby et al., 1997; Selley et al., 1997; Kaplan et al., 1998; McLeman et al., 2000) , methamphetamine (Iwasa et al., 1996; Ujike et al., 1996; McLeman et al., 2000; Nishio et al., 2002; Schmauss et al., 2002; Kitanaka et al., 2003; Tong et al., 2003; Yang et al., 2008) , and cocaine (Kleven et al., 1990; Nestler et al., 1990; Terwilliger et al., 1991; Striplin and Kalivas, 1992; Self et al., 1994; Henry and White, 1995; Volkow et al., 1999; Morgan et al., 2002; Xi et al., 2002; Kobayashi et al., 2007) addiction models. Thus, since the recent discovery of the AGS and RGS heterotrimeric G-protein modulators, the potential involvement of these molecules in addiction has been an active area of research.
G-protein modulators: Activator of G-protein Signaling 3 and the Regulators of G-protein Signaling family
Yeast-based functional assays for receptor-independent activation of heterotrimeric G-protein signaling using mammalian cDNAs showed four structurally and functionally unique 'non-receptor AGS3' proteins Takesono et al., 1999; Cao et al., 2004) . Given the stark structural and functional dissimilarities among the AGS proteins, new nomenclature has been assigned . Nonetheless, within the addiction literature, the older nomenclature predominates. Of the AGS proteins, only AGS3 has been evaluated in addiction models. AGS3 is a highly conserved G-protein dissociation inhibitor (GDI, Fig. 2b ) Bernard et al., 2001; Peterson et al., 2002; De Vries et al., 2000a) . In brief, a GDI prevents activation of the G-protein Ga subunit. AGS3 was also among the first GDI described that simultaneously stimulates signaling through Gbg while inhibiting Ga activation and association of G-protein with receptor. Moreover, although AGS3 was first described in a receptor-independent functional screen, it is most likely to inhibit Ga and stimulate Gbg subsequent to receptor activation (Webb et al., 2005) .
Of the 30 and above members of the RGS family, all share a RGS homology domain (RGS box) that imparts to all the currently known RGS proteins GTPase-accelerating protein (GAP) activity on Ga i /o and Ga q G-protein subunits (Berman and Gilman, 1998; Ross and Wilkie, 2000; De Vries et al., 2000b; Hollinger and Hepler, 2002) . A GAP promotes G-protein deactivation and can thereby limit and/or focus signaling through G-protein-coupled receptors. However, other proteins that do not function like RGS, such as RhoGEF, GRK, and Conductin, also contain the RGS box. Research describing the role of the RGS family in addiction (predominantly the psychostimulants and opiates) has been the topic of several reviews (Neubig, 2002; Burchett, 2005; Ron and Jurd, 2005; Traynor and Neubig, 2005; Garzon et al., 2008; Hooks et al., 2008; Lomazzi et al., 2008; Traynor, 2010) . In brief, most studies on RGS and addiction have focused on mRNA levels rather than on protein. Depending on the substance studied and the paradigm applied, RGS mRNA 
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The heterotrimeric G-protein cycle. (a) Intracellular heterotrimeric G-proteins consist of an a subunit and a tightly associated b-g complex. The G-protein heterotrimer is inactive and usually receptor-associated when the a subunit (Ga) is bound to guanosine diphosphate (GDP) and Gbg (GaKGDPbg).
Step 1: receptor activation facilitates mass-action exchange of guanosine triphosphate (GTP) for GDP, which lowers affinity of the GTP-bound G-protein (GaKGTPbg) for receptor. Additionally, the activated Ga (Ga bound to GTP, GaKGTP) dissociates from the Gbg complex (Gilman, 1987; Bourne, 1997) .
Step 2: both GaKGTP and Gbg can modulate diverse second messenger effectors (Ross, 1989) .
Step 3: Ga terminates its own signaling by hydrolyzing GTP into GDP, releasing inorganic phosphate.
Step 4: GaKGDP exhibits higher Gbg affinity.
Step 5: reassembled G-protein heterotrimer (GaKGDPbg) can reassociate with receptor, which increases receptor affinity for ligand (Lorenzen et al., 2000) . (b) Activator of G-protein Signaling 3 (AGS3) catches and stabilizes inactive Ga i (open arrow), which augments signaling through Gbg-mediated effectors (closed arrow), but inhibits signaling through Ga i -coupled receptor onto effector, while also prohibiting G-protein heterotrimer reformation and receptor re-association (open arrow) De Vries et al., 2000a; Natochin et al., 2001; Webb et al., 2005) .
is often elevated or decreased in brain structures relevant to addiction and pain (Traynor and Neubig, 2005) and, through increased GAP activity modulating metabotropic receptor signaling, may regulate the behavioral impact of addictive drugs (Kenny and Markou, 2004) . Intriguingly, while RGS4 mRNA upregulation in preclinical addiction studies is not as dramatic as some other RGS family mRNA (Traynor, 2010) , RGS4 protein was found to be acutely upregulated in the rat locus coeruleus after chronic morphine (Gold et al., 2003) and inducible RGS4 knockouts displayed a profound morphine phenotype (Han et al., 2010) . A similar time-dependent protein expression profile has been reported for RGS9-2 and RGS7 after acute morphine (Traynor, 2010) . However, only a small rise in RGS9-2 protein is observed after chronic morphine, and this upregulation is often disconnected from mRNA expression (Traynor, 2010) . Thus, studies on the RGS family have shown a sophisticated repertoire in ameliorating and facilitating psychiatric conditions, including response to addictive drugs. However, owing to space limitations, the interested reader is referred to the primary literature discussed in the studies cited above.
Activator of G-protein Signaling 3: structure and function
Higher organisms express one AGS3 homolog, Leu-Gly-Asn repeat-enriched protein/G-protein signaling modulator 2, that along with AGS3 is found in several rat tissues including neurons, astroglia, and microglia (Blumer et al., 2002; McCudden et al., 2005) . Full-length AGS3 is enriched in brain and testes, and primary cortical culture suggests that AGS3 may be predominantly neuronal (Blumer et al., 2002) .
Rat AGS3 consists of 650 residues encompassing tandem repeats in both the amino terminus and carboxyl terminus. The amino terminus includes seven tetratricopeptide repeats (TPR) that form a coiled-coil domain of antiparallel helices that can modulate protein-protein and proteinmembrane interactions (Das et al., 1998; Blatch and Lassle, 1999) . Intriguingly, in protein phosphatase 5, the aminoterminal TPR domains regulate the catalytic carboxyl terminus (Kang et al., 2001) . However, no regulatory function of AGS3 TPR has been observed. Instead, AGS3 TPR is thought to mediate compartmentalization or scaffolding, as TPR deletion results in a homogenous, cytoplasmic distribution (Pizzinat et al., 2001) .
The amino-terminal AGS3 TPR repeats are followed by approximately 100 amino acid linker and four conserved approximately 25 amino acid carboxyl-terminal G-protein regulatory motifs known as GPR or GoLoco (Siderovski et al., 1999; Takesono et al., 1999; Natochin et al., 2000; De Vries et al., 2000a; Adhikari and Sprang, 2003; Siderovski and Willard, 2005) . The GPR motif is also found in other proteins including RGS14 ( Intriguingly, although all four AGS3 GPR motifs differ in primary sequence and affinity (Natochin et al., 2000; De Vries et al., 2000a; Adhikari and Sprang, 2003) and as surrounding residues seem to determine both affinity and GDI efficacy (Luo and Denker, 1999; Ponting, 1999; Siderovski et al., 1999; Kimple et al., 2001; Kimple et al., 2002; Adhikari and Sprang, 2003) , the carboxyl-terminal GPR domains of AGS3 are both necessary and sufficient for GDI activity on Gai De Vries et al., 2000a; Pizzinat et al., 2001) . Moreover, each of the GPR domains can function independently and also perhaps cooperatively as a GDI on Ga i1 (Adhikari and Sprang, 2003) . Together, these data suggest that each GPR repeat can bind Ga independently and/or cooperatively (Adhikari and Sprang, 2003) .
Together with site-directed mutagenesis (Natochin et al., 2002; Willard et al., 2008) and simulated molecular dynamic (Khafizov, 2009 ) studies, crystal structures of the GPR motif bound to chimeric Ga (Kimple et al., 2002) have been solved and subsequently have shown an elegant mechanism of AGS3 GDI involving both stabilization of inactive conformations and steric hindrance. Thus, AGS3 binding Ga is thought to regulate guanine nucleotide exchange and may also physically occlude the guanosine diphosphate (GDP) exit route of Ga (Kimple et al., 2002; Natochin et al., 2002; Willard et al., 2008; Khafizov, 2009 ). Together, these data suggest that AGS3 is an effective GDI preventing Ga activation by both stabilizing inactive Ga and physically preventing Ga activation ( Fig. 2b) .
Importantly, AGS3 binding is not selective for Ga i , as Ga t and weak Ga o and Ga q binding has also been observed, but AGS3 only exhibits GDI activity at Ga i and Ga t De Vries et al., 2000a; Bernard et al., 2001; Natochin et al., 2001; McCudden et al., 2005) . Ga t is enriched in the retina whereas the brain is enriched with Ga i/o . Thus, through TPR and GPR motifs, brain AGS3 may scaffold a complex Ga mixture at the membrane to increase signaling efficiency through G-protein-coupled receptors (Siderovski et al., 1999; Bernard et al., 2001; Pizzinat et al., 2001; Natochin et al., 2002) and perhaps facilitate second messenger crosstalk (Fan et al., 2009 ). This action is contrasted with the RGS family that seems to preferentially accelerate deactivation of Ga i/o , Ga q , and the cognate Gbg.
In summary, AGS3 preferentially binds to, and stabilizes, all three Ga i isoforms in the GDP bound inactive state (Fig. 2 ) through GPR domains that inhibit guanine nucleotide exchange. Guanine nucleotide exchange (GTP for GDP) is necessary for heterotrimeric G-protein activation. In this manner, AGS3 inhibits subsequent Ga i activation while simultaneously facilitating signaling through the now displaced Gbg complex (Fig. 2) De Vries et al., 2000a; Webb et al., 2005) . Thus, AGS3, the AGS3 structure, expression, and function Bowers 503 first GDI described for heterotrimeric G-proteins can dramatically shape the signaling through Ga i -coupled receptors.
Relevance of Activator of G-protein Signaling 3 to addiction
The following sections summarize data collected over the past decade beginning with expression profiling and moving on to functional studies that assay both neurochemistry and behavior.
AGS3: expression profile in addiction models
In rat models of alcoholism and cocaine addiction, AGS3 expression has been examined in a limited number of mesocorticolimbic regions. An upregulation of approximately 60% was detected in the NAcore and PFC 3 or more weeks after either repeated cocaine injections or 3 weeks extinction from operant cocaine self-administration. AGS3 expression did not change in several other mesocorticolimbic regions at these time points. Intriguingly, after cocaine, AGS3 upregulation seems to require both repeated cocaine exposure and a protracted abstinence period (Bowers et al., 2004) . Intriguingly, mRNA encoding AGS3 remained unchanged in both the NAcore and PFC 3 weeks after repeated cocaine injections (Bowers, unpublished observations) , suggesting that AGS3 expression is not transcriptionally regulated. In fact it was recently shown that AGS3 expression can be regulated by a ubiquitin specific protease (USP9x) in vitro and that AGS3 and USP9x can be co-regulated in the rat PFC 3 weeks after repeated cocaine injections (Xu et al., 2010) .
The dynamics of AGS3 protein expression in rat NAcore and PFC is not equivalent. For example, approximately 60% of the AGS3 protein upregulation observed in the PFC 3 weeks after repeated cocaine injections decreased to approximately 30% in a separate cohort 8 weeks after repeated cocaine injections (Bowers et al., 2004) . Thus, although still significantly elevated, rat PFC AGS3 content declined between the 3 and 8 weeks cocaine abstinence time points. In contrast, no decline was observed in the rat NAcore between the 3 and 8 weeks cocaine abstinence time points. This regional distinction was also apparent during alcohol abstinence . For example, AGS3 protein was upregulated to approximately 25% in the NAcore 3 weeks after operant ethanol self-administration. No AGS3 expression change was observed in PFC or several other mesocorticolimbic regions after ethanol self-administration. Further, NAcore AGS3 expression returned to baseline after 6 additional weeks. Intriguingly, AGS3 expression changes may be dose-responsive to alcohol (a dose-dependent upregulation was observed 3 weeks after repeated ethanol injections: Bowers, unpublished observations and Bowers et al., 2008, supplemental) .
Taken together, these data suggest that AGS3 expression is not altered by repeated exposure to commonly abused substances until after protracted abstinence. Thus, initial drug sensitivity or mechanisms that support ongoing drug taking are unlikely to be mediated through changes in AGS3 expression. In partial support of this hypothesis, brief (10 min) opioid receptor activation on primary striatal neurons in vitro facilitated AGS3 binding to inactive Ga subunits (Yao et al., 2005) . However, AGS3 protein upregulation and the subsequent superactivation of downstream signaling occurred only as a function of morphine washout (Fan et al., 2009) . The upregulation of AGS3 in brain regions that are implicated in motivation, reinforcement, and reactivity to drug-associated cues during abstinence from commonly abused substances led to the hypothesis that AGS3 modulates critical aspects of drug and alcohol relapse. Data testing this hypothesis are described next.
Neurobiology of cocaine and cocaine relapse: role of Activator of G-protein Signaling 3
Repeated cocaine injections normally augment the motoric and neurochemical response to a subsequent cocaine challenge (Post and Rose, 1976) . This sensitization effect is typically more pronounced after abstinence (Izenwasser and French, 2002) , contains elements of conditioning, and has been associated with the reinstatement of drug-seeking behavior (De Vries et al., 1998) . Intriguingly, pertussis toxin injection (that prevents Ga i/o dissociation and activation) into the NAcore (Hummel and Unterwald, 2003) or ventral tegmental area (Steketee and Kalivas, 1991) increased behavioral sensitization to cocaine, and expression of sensitization is decreased by activation of a Ga i/o -coupled receptor (Beyer and Steketee, 2002; Xie and Steketee, 2009 ).
During abstinence from repeated cocaine injections, AGS3 knockdown prevented the uncoupling of Ga i from receptor (Bowers et al., 2004) . Further, AGS3 knockdown restored Ga i receptor coupling to drug-naive levels and prevented the expression of cocaine-mediated behavioral sensitization. Importantly, after antisense washout, AGS3 expression returned and behavioral sensitization to cocaine challenge was expressed (Bowers et al., 2004) . Thus, during cocaine abstinence, AGS3 expression increased, signaling through Ga i -coupled receptors decreased, and behavioral sensitization was expressed. However, if PFC AGS3 is knocked down, signaling through Ga i -coupled receptors is increased to drug-naive levels and expression of behavioral sensitization is blocked. Thus, AGS3 expression seems to gate cocaine-mediated sensitization. Importantly, AGS3 knockdown does not change the locomotor response to a novel environment, injection stress, or acute cocaine.
Complimentary experiments to this reversible knockdown were performed with a cell-permeable AGS3-like mimetic peptide (Bowers et al., 2004 ) containing a single GPR consensus motif derived from the carboxyl-terminal AGS3 GPR repeats (Peterson et al., 2002) . This peptide, similar to AGS3 upregulation, binds inactive Ga i and uncouples the cognate receptor (Bowers et al., 2004) . This is not observed with a similar peptide containing a point mutation. Injection of the AGS3 mimetic peptide into the drug-naive PFC, followed by acute, systemic cocaine induced a sensitized-like behavioral and neurochemical response similar to that observed after abstinence from repeated cocaine exposures (Fig. 3) (Bowers et al., 2004) . Neither the sensitized behavioral nor neurochemical response was observed after acute systemic cocaine if the mutant peptide was injected into the PFC instead of the AGS3 mimetic peptide. Neither AGS3 mimetic nor mutant peptide altered the locomotor or neurochemical response to systemic saline. Taking these data together with the knockdown data described above leads to the interpretation that AGS3 expression levels gate some behavioral and neurochemical plasticity that is commonly observed during abstinence from repeated cocaine exposure.
Given the intriguing role of AGS3 to modulate some of the neurochemistry thought to be involved in cueprimed, cocaine-primed, or heroin-primed relapse (Park et al., 2002; McFarland et al., 2003 McFarland et al., , 2004 LaLumiere and Kalivas, 2008) , the propensity to relapse into cocaineseeking behavior was assayed after reversible AGS3 knockdown or treatment with the AGS3-like mimetic peptide (Bowers et al., 2004) . Figure 4a illustrates that subjects were trained to press a lever to receive a cocaine infusion or food reinforcement. Once this responding was stable, lever pressing was extinguished by removing the reinforcer. During this drug-free period, AGS3 expression increased (data not shown in Fig. 4 ). AGS3 knockdown did not affect food-primed reinstatement of food-seeking behavior (Fig. 4b ), yet cocaine-primed seeking of cocaine was blocked (Fig. 4c ). However, a cocaine-prime elicited drug-seeking in rats where the PFC was treated with scrambled oligonucleotide (Fig. 4c and d) . Nonetheless, after antisense washout and return of AGS3 protein, cocaine-prime reliably precipitated relapse in the same rats that failed to reinstate drug-seeking under AGS3 knockdown (Fig. 4d) . Perhaps most intriguingly, injection of the AGS3-like mimetic peptide into the PFC shifted the cocaine-dose response for drug-primed relapse leftward (Fig. 4e) . In summary, AGS3 expression levels seem to gate several cocaine addiction-associated neurochemical and behavioral phenomena including sensitivity to cocaine-primed relapse, expression of behavioral and neurochemical sensitization, and uncoupling of at least two receptors signaling through Ga i .
Despite the apparent congruity of these data, the precise mechanism of AGS3 protein induction and the primary class of affected receptors remains unknown. For example, it was speculated earlier that AGS3 protein accumulation was not regulated by transcriptional processes and it has been recently shown that a ubiquitin specific protease (USP9x) can regulate AGS3 expression (Xu et al., 2010) , yet the transduction pathways impinging upon this promising mechanism have not been elucidated. Moreover, although it was shown that AGS3 knockdown after multiple cocaine injections can restore the diminished coupling of the D2-like dopamine receptor to drug naive levels and AGS3 knockdown prevents cocaine-precipitated relapse, it remains exceptionally unlikely that highly efficacious (Gal and Gyertyan, 2006; Karila and Reynaud, 2009 ) D2like dopamine agonists would serve as antirelapse medications Edwards et al., 2007; Bachtell et al., 2008) until pharmacogenetics (Blum et al., 2009) or promiscuous ligands (Pilla et al., 1999; Khroyan et al., 2000; Preti, 2000; Gasior et al., 2004; Feltenstein et al., 2007) are more widely adopted.
Heroin relapse: role of Activator of G-protein Signaling 3
The reinforcing effects of heroin are mediated through m-opiate receptors (Matthes et al., 1996) that couple through Ga i to acutely inhibit AC activity. During continued opiate receptor stimulation (Sharma et al., 1975; De Vries et al., 1991) and during opiate blockade, washout, or withdrawal (Avidor-Reiss et al., 1995; Schoffelmeer et al., 1995; Watts, 2002; Fan et al., 2009) , the increase in AC activity has been associated with opiate tolerance and dependence (Sharma et al., 1975; Van Vliet et al., 1992 , 1993 Chao and Nestler, 2004) . Precisely, how AC activity increases during opiate withdrawal remains unknown. 
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Increased Activator of G-protein Signaling 3 (AGS3) facilitates cocaine, but not food seeking. (a) Time-line outlining the experimental protocol. (b) Bilaterally reducing AGS3 did not effect reinstatement of food seeking. However, (c) AGS3 knockdown blocked the reinstatement of cocaine-seeking behavior, whereas infusion with scrambled oligonucleotide had no effect. (d) Reinstatement of drug-seeking was initiated by a cocaine injection 2 weeks after discontinuing oligonucleotide infusion in all groups. (e) Microinjection of Tat-G-protein regulatory motif (GPR) into the prefrontal cortex augmented the reinstatement of drugseeking (active lever pressing) by a cocaine priming injection (5 mg/kg, intraperitoneal). Two reinstatement trials were conducted in subjects extinguished to criterion (extinction I and extinction II), and Tat-GPR or Tat-mGPR were administered 30 min before the cocaine priming injection in random order. Data points depict mean active lever presses + standard error of mean, n = 8-9. Ext, total active lever presses made during the extinction trial the day before the cocaineinduced reinstatement trial; Test, total active lever presses made during cocaine reinstatement; Retest, total active lever presses after a second extinction period and a second cocaine reinstatement; SC, scrambled oligonucleotide. *P < 0.05, using two-way analysis of variance with repeated measures over time, and a least significant difference test for post-hoc comparisons. Reprinted from Bowers et al. (2004) , with permission from Elsevier.
Thus, it is intriguing that the AGS3 stabilization of GDP-bound Ga i liberates Gbg (see Fig. 2 ), which can subsequently stimulate signaling through Gbg-mediated effectors Natochin et al., 2000; Bernard et al., 2001; Webb et al., 2005; Ferre et al., 2008) including some AC isozymes (Yao et al., 2005) . Importantly, AGS3 protein expression increased during morphine withdrawal, and AGS3 acted as a central molecular mediator of signaling pathway crosstalk that culminated in increased AC activity (Fan et al., 2009) . The fact that AGS3 upregulation during morphine withdrawal can stimulate AC type 5 (Fan et al., 2009 ) is especially intriguing because striatial regions, including the NAcore, are enriched with AC5 (Defer et al., 2000) and AC5 has been implicated in opiate tolerance and withdrawal (Avidor-Reiss et al., 1997) . Accordingly, the knockdown of rat NAcore AGS3 during heroin abstinence blocked heroin-primed relapse (Yao et al., 2005) . Taken together, AGS3 seems to represent a critical molecular integrator leading to AC heterologous sensitization after prolonged m-opiate receptor activation or withdrawal, and AGS3 expression gates the propensity of heroin to precipitate relapse.
Alcohol relapse: role of Activator of G-protein Signaling 3
The role that AGS3 may play in cocaine and heroin addiction was probed after small doses of researcheradministered drugs used to precipitate relapse. Compared with these drugs, alcohol only weakly primes relapse in laboratory rodents (Stewart, 2000; Le and Shaham, 2002) . However, by manipulating conditions governing alcohol availability and by presenting compound stimuli associated with alcohol earlier Bowers et al., 2008) , robust relapse can be obtained with standard, outbred rats, and alcohol-seeking motivation quantified .
Abstinent alcoholics are prone to relapse (Larimer et al., 1999) because of a heightened motivation to seek alcohol (Sanchis-Segura and Spanagel, 2006) . Increased alcoholseeking during abstinence is expressed by humans (Burish et al., 1981) , nonhuman primates (Weerts et al., 2006) , and rodents (Sinclair and Senter, 1968; Sanchis-Segura and Spanagel, 2006) . Intriguingly, during prolonged abstinence, this motivation can be cue-driven rather than pharmacologically-driven and regulated by NAcore AGS3 protein expression . In other words, the heightened motivation to seek alcohol after abstinence can be primed and maintained by cues associated earlier with alcohol alone, and rat NAcore AGS3 knockdown significantly interferes with the expression of this motivation to seek alcohol. More specifically, after prolonged alcohol abstinence, AGS3 knockdown reversed both the fast and persistent response ultrastructure exhibited during alcohol-seeking without impairing motoric capacity or cue-primed sucrose-seeking during abstinence from operant sucrose self-administration ( Fig. 5 ).
AGS3 liberates Gbg upon binding GDP-GDP-Ga i (see Fig. 2 ) and at least part of the AGS3 contribution to heightened, cue-precipitated alcohol-seeking during prolonged abstinence is mediated through Gbg, as Gbg sequestration partially blocked alcohol-seeking behavior . However, AGS3 knockdown does not block the motivation of sucrose-abstinent rats to seek sucrose ( Fig. 5f and g) . Thus, the increased motivation to seek alcohol and reactivity to alcohol-related cues that develop during prolonged abstinence, and that drive relapse, may be modulated through AGS3. Intriguingly, AGS3 is not upregulated after brief, 24 h, abstinence, and AGS3 knockdown does not impact motivation to seek alcohol after short-term abstinence.
Is Activator of G-protein Signaling 3 upregulation behaviorally relevant?
Although the AGS3 addiction-related data described above seem compelling, studies probing the role of AGS3 in cocaine (Bowers et al., 2004) and heroin (Yao et al., 2005) relapse models only investigated the efficacy of a drug-prime to precipitate drug-seeking behavior. Thus, the study evaluating the capacity of AGS3 knockdown and Gbg sequestration to normalize the cue-primed motivation to seek alcohol during abstinence represents an important advance to our understanding of the AGS3 repertoire. Specifically, in this new alcohol 'relapse' model, the motivation to seek alcohol is not only robust and reproducible, but cue-driven, and also independent of alcohol reinforcement. In other words, no environmental renewal is observed during alcohol abstinence, as alcohol-seeking behavior was not primed upon the omission of cues associated earlier with alcohol. However, after abstinence, the cue-primed navigation of the progressive ratio schedule by alcohol-reinforced rats is strikingly similar to that expressed by alcohol-abstinent rats responding for cues previously associated with alcohol alone (not alcohol reinforced). In these cue-only experiments, a clear plexiglass barrier prevented access to the alcohol-containing cup. Thus, these alcohol-abstinent rats experienced all cues except those specifically related to alcohol ingestion, yet the breakpoints obtained, cumulative responding, run rate, and inter-response interval profile overlaid with alcohol reinforced rats.
Thus, the motivation to seek alcohol after abstinence in this paradigm may be cue-driven and also potentially linked to NAcore excitability (Hopf et al., 2010) . However, the effect of AGS3 knockdown on alcoholseeking behavior was only evaluated in cued and alcohol reinforced rats . Although the efficacy of AGS3 knockdown under these 'real world' conditions is promising, the capacity of AGS3 to modulate response to drug-associated cues has not been explicitly evaluated in any addiction model to date. Nonetheless, increased EtOH presses EtOH presses (%) * * * *
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Activator of G-protein Signaling 3 (AGS3) knockdown reduced the enhanced alcohol seeking during abstinence. (a) Antisense knocked down AGS3 in the nucleus accumbens core of 3 week-alcohol abstinent rats [scrambled (SC)-AGS3: n = 7; AS-AGS3: n = 7] and in 24 h-abstinent rats (SC-AGS3: n = 6; AS-AGS3: n = 6). Representative AGS3 and calnexin control blots at 3 weeks are shown (a 0 ). (b) AGS3 knockdown (AS-AGS3) reduced alcohol seeking in 3 week-abstinent rats to 24 h-abstinent levels (n = 12), with no effect in 24 h-abstinent rats (n = 12), whereas a scrambled control construct (SC-AGS3) had no effect on motivation (breakpoint) at 3 week-abstinence (n = 15). (c and d) Reduced motivation to seek alcohol in 3 week-abstinent rats was also evident throughout the progressive ratio testing period in terms of reduced cumulative responding (c) and in decreased number of fast and slow interresponse intervals AGS3 protein expression during alcohol abstinence was significantly correlated to both the expression of this enhanced cue-primed motivation to seek alcohol during abstinence and to the earlier operant alcohol selfadministration history.
Thus, upregulated AGS3 may increase drug efficacy at eliciting drug-seeking behavior or sensitization. However, the contribution of 'low dose' drug-mediated interoceptive cues in priming AGS3-modulated drug-seeking behavior and sensitization, versus the purely pharmacological effects of drug-prime interacting with AGS3, has not been fully elucidated either. Although, it was shown that AGS mimetic peptides shift the dose response curve of cocaine-primed relapse leftward (Bowers et al., 2004) . Thus, it is intriguing that AGS3 upregulation seems to require abstinence from multiple drug exposures. Nonetheless, AGS3 may also modulate drug-associated cue reactivity, as AGS3 knockdown not only reduced breakpoint during cue-primed, but also reinforced alcoholseeking to pre-abstinence levels; time to first response, run rate, and inter-response intervals were also returned to pre-abstinence levels .
Intriguingly, AGS3 knockdown during cocaine abstinence blocked the expression of behavioral sensitization to cocaine, but AGS3 knockdown before cocaine exposure failed to block behavioral sensitization to cocaine (Bowers et al., 2004) . AGS3 knockdown also failed to impede the motoric response to novelty, mild restraint stress, or acute cocaine injection. Moreover, AGS3 knockdown also failed to block food-primed reinstatement of food-seeking or cueprimed reinstatement of liquid sucrose-seeking (both during abstinence from operant sessions), suggesting that changes in AGS3 expression may be relatively specific for drug-related stimuli. This is in contrast to alcoholism pharmacotherapies such as naltrexone that also reduces concurrent alcohol and sucrose-seeking behaviors (Bienkowski et al., 1999; Steensland et al., 2007) .
Together, these data suggest that an AGS3 upregulation may be pathogenic only after abstinence from repeated drug exposures and, that when upregulated, that AGS3 may modulate either or both the response to drug-related pharmacology or earlier associated cues.
AGS3 insights informing a therapeutic future
Data summarized above suggest that AGS3 could represent an etiological molecular gateway of cocaine, heroin, and alcohol addiction. Importantly, AGS3 knockdown during cocaine abstinence restored the diminished signaling through Ga i -coupled receptors to drug-naive levels (Bowers et al., 2004) . Decreased Ga i -coupled receptor signaling capacity is seen in rat strains with increased responsiveness to repeated cocaine (Haile et al., 2001) or morphine (Guitart et al., 1993) , in nonhuman primates self-administering cocaine (Morgan et al., 2002) , and in human addicts (Volkow et al., 1999; Heinz et al., 2005; Martinez et al., 2005; Watanabe et al., 2008) . These data suggest that decreased Ga i signaling may support addiction pathogenesis. Importantly, AGS3 knockdown, unlike current addiction pharmacotherapies (e.g. naltrexone or acamprosate), does not impair seeking of nonaddictive substances (Figs 4b, 5f and g) or motoric capacity (Figs 4b and 5e-g) , including under conditions of drug-seeking and the drug-free response to mild stress or novelty (Bowers et al., 2004 .
Thus, increased AGS3 expression seems to be a deleterious gatekeeper on the path towards addiction. Unfortunately, clinical knockdown strategies face significant barriers and receptor-mediated approaches are limited by a potential ubiquitous promoter or enhancer upstream of AGS3 (Fan et al., 2009) . Nonetheless, the robust structural and functional information summarized above, can inform rational design of AGS3-targeted antagonists. For example, the necessary residues of AGS3 binding (Peterson et al., 2002; Willard et al., 2008) and action (Kimple et al., 2002 (Kimple et al., , 2004 on Ga i have been identified and confirmed in crystal structures of an AGS3-like GPR motif bound to chimeric Ga (Kimple et al., 2002) . Together these data can inform design of small, peptide mimetics that can selectively disrupt the Janus-like nature of AGS3; that is, binding to Ga i and liberating Gbg or GDI activity on Ga i . Selectively disrupting binding would simultaneously augment signaling through Ga i -coupled receptors and focus signaling through Gbg-mediated effectors. Leaving binding intact and disrupting GDI activity would leave signaling through Ga i -coupled receptors dampened or perhaps would further augment signaling through Gbg. Thus, the potential to tailor treatment to the individual's current experience with the drug, abstinence status, or motivational level exists (Yao et al., 2005; Bowers et al., 2008; Fan et al., 2009 ).
